Platform of Science & Expertise

Preclinical Services

MD Biosciences AAALAC accredited Preclinical Services Laboratories provide exclusive, in-depth studies in the core areas of immunology, inflammatory diseases and neurology. Therapeutic areas include cancer, with particular focus on onco-immunology, joint, respiratory, gastrointestinal and skin inflammation, wound healing and metabolic studies. Pain and neurodegenerative diseases form the core of our strong CNS and neurological studies area. Studies are accompanied by a host of in vitro methodologies including multiplex protein analysis, qPCR, flow cytometry, histology and immunohistochemistry, offering the opportunity to investigate mode of action of candidate drugs.


Biomarker and Central Laboratory Services

MD Biosciences provides extensive biomarker expertise through its CLIA Clinical Laboratory Services Division, one of the largest independent, regional diagnostic laboratories in the upper Midwest of the United States. Our technological capabilities include molecular and proteomic biomarker analysis, assay development and CLIA-validation as well as central laboratory functionality for clinical trials. Our services are rounded out with routine clinical chemistry, urinalysis and hematology analyses. Learn more about our comprehensive services menu and what our laboratory can do for your studies!


MD Biosciences Research Products

MD Biosciences develops monoclonal antibodies, proteins and assays through the course of its research. Such products are manufactured and provided for sale through our dedicated offices and representatives throughout the world. Discover our products including the ArthritoMAB® antibody cocktail for induction of arthritis, our bovine collagen products, Neurofreeze® for the preservation of neuronal cells, our unique anti-mouse IgD for the study of B-cell activation and many other exciting products.


Collaborative Drug Development

Learn about our emerging pipeline of lead compounds addressing unmet needs at the cross-section of inflammation and pain. Our pipeline includes lead, first-in-class, non-opioid compounds for the therapy of neuropathic and chronic pain as well as vectorized vaccine for canine osteosarcoma with its equivalent in development for human therapeutic applications. Collaborative activity is supported by InnovX®, the platform for taking nascent technologies from bench to lead status. Talk to us about our collaboration and investment possibilities.


Have Questions? Contact Us


MD Biosciences Announces Launch of Salspera, LLC To Advance Saltikva® (MDB401B) ...

Jul 18, 2017 3:26:21 PM

MD Biosciences is proud to announce the launch of Salspera, LLC ( to ... Read More


Apr 20, 2017 2:20:14 PM

Saint Paul, MN, April 20, 2017     Five leading research organizations have partnered to ... Read More

 Upcoming Events

5th Annual Immuno-Oncology Summit

Aug 28-Sept 1, 2017 (Boston, MA, USA)

4th Annual Meeting of The Institute for Medical Research Israel-Canada

September 5-7 (Eilat, Israel)

10th Annual Congress of the European Pain Federation

September 6-9 2017 (Copenhagen, Denmark)

Outsourcing in Clinical Trials - New England

September 6-7, 2017 (Boston, MA, USA)

Dermatology Drug Development Summit 2017

October 10-12, 2017 (Boston, MA, USA)

47th Annual Meeting of the Society for Neuroscience

November 11-15, 2017 (Washington D.C, USA)